abatacept
Abatacept (Orencia) is a biologic medicine that calms overactive immune responses by blocking a key step in T-cell activation. It is used to treat rheumatoid arthritis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and to help prevent acute graft-versus-host disease after stem cell transplant.
This page is based on EMA and FDA prescribing information for abatacept, cross-checked with DailyMed labeling and the National Cancer Institute drug dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
T cells are like soldiers who need two keys to spring into action: one from recognizing the enemy and a second 'go' signal from a handshake with another cell. Abatacept steps in front of that second handshake, so the T cell stays calm and does not attack the body's own joints and tissues.
In simple terms
Abatacept is an engineered protein that blocks a step needed to fully activate T cells, a type of white blood cell involved in inflammation. Normally, T cells need two signals to switch on: one from recognizing a target and a second costimulatory signal delivered through CD28. Abatacept binds to the molecules that would normally deliver that second signal, preventing T cells from becoming fully activated. By calming T-cell activity, abatacept reduces the inflammation that damages joints in rheumatoid arthritis and psoriatic arthritis, and it also helps prevent immune cells from attacking transplanted stem cells.
In depth
Abatacept is a recombinant fusion protein consisting of the extracellular domain of human CTLA-4 linked to a modified Fc portion of human IgG1. CTLA-4 binds with high affinity to CD80 (B7-1) and CD86 (B7-2) on antigen-presenting cells, competing with CD28 for these ligands and thereby blocking the costimulatory signal required for full T-cell activation. By inhibiting T-cell activation, abatacept reduces pro-inflammatory cytokine production, decreases leukocyte infiltration into inflamed tissues, and suppresses the immune responses that drive rheumatoid arthritis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis. In the setting of hematopoietic stem cell transplantation, abatacept prevents donor T cells from recognizing host antigens, thereby reducing the incidence of acute graft-versus-host disease.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
T cells are like soldiers who need two keys to spring into action
- Normally, T cells need two signals to switch on: one from recognizing a target and a second costimulatory signal delivered through CD28.
- Abatacept binds to the molecules that would normally deliver that second signal, preventing T cells from becoming fully activated.
- Abatacept steps in front of that second handshake, so the T cell stays calm and does not attack the body's own joints and tissues.
- By calming T-cell activity, abatacept reduces the inflammation that damages joints in rheumatoid arthritis and psoriatic arthritis, and it also helps prevent immune cells from attacking transplanted stem cells.
Target: CD80/CD86 (B7-1/B7-2)
Costimulatory molecules on antigen-presenting cells that bind CD28 on T cells to deliver the second signal required for full T-cell activation; abatacept blocks this interaction.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in European Union
EMA- Treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs including methotrexate or a TNF-alpha inhibitor.
- Treatment of highly active and progressive rheumatoid arthritis in adult patients not previously treated with methotrexate.
- Treatment of active psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate.
- Treatment of moderate to severe active polyarticular juvenile idiopathic arthritis in paediatric patients 2 years of age and older who have had an inadequate response to previous DMARD therapy.
Approved uses in United States
FDA- Treatment of adult patients with moderately to severely active rheumatoid arthritis.
- Treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis.
- Treatment of patients 2 years of age and older with active psoriatic arthritis.
- Prophylaxis of acute graft-versus-host disease in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation from a matched or 1 allele-mismatched unrelated donor.
Approved uses in United States
DailyMed- Treatment of adult patients with moderately to severely active rheumatoid arthritis.
- Treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis.
- Treatment of patients 2 years of age and older with active psoriatic arthritis.
- Prophylaxis of acute graft-versus-host disease in combination with a calcineurin inhibitor and methotrexate.
Official sources
The statements on this page trace back to these records.
- Orencia (abatacept) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- U.S. Food and Drug Administration: abatacept prescribing information
U.S. Food and Drug Administration
- DailyMed: ORENCIA labeling
DailyMed, U.S. National Library of Medicine
- National Cancer Institute: abatacept
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.